Author: Daniel E. Casey Publisher: Springer Science & Business Media ISBN: 3642732801 Category : Medical Languages : en Pages : 326
Book Description
The landmark description by Delay and Deniker in 1952 of chlorpromazine's effect in psychosis suddenly eclipsed all other progress in psychopharmacology over the previous centuries. Since this report 35 years ago, a vast amount of research has contributed to the major advances in treatment that have improved the lives of millions of patients who would otherwise be incapacitated by their psychiatric disorders. This research has also led to valuable new insights into the causes of mental illnesses and the mechanisms of action of therapeutic drugs. However, there is much more work to be done. Thus, it is of great value periodically to assess the present state of knowledge as a first step to charting future directions. This symposium held in Denmark in 1987 covered many critical issues in psychopharmacology. The etiology, pathogenetic mechanisms, clinical aspects, and future directions of research in schizophrenia, affective disorders, anxiety, and dementia are addressed. Several of the problems with current therapeutic agents, such as side effects and limited efficacy, are also reviewed. Preclinical strategies with existing and new animal and computer models are discussed to point the way for developing better psychopharmacologic treatments of all psychiatric disorders.
Author: W.B. Essman Publisher: Springer Science & Business Media ISBN: 9401181233 Category : Medical Languages : en Pages : 287
Book Description
The areas of experimental and clinical psychopharmacology have continued to grow in terms of the numbers of studies appearing in the literature as well as the activity generated by other disciplines that has influenced the output of behavioral pharmacology research. Psychoactive drugs have been considered for their comparative effects upon selected behaviors or for their effect upon diverse behaviors. Behavioral circum stances certainly influence not only the metabolism and action of psycho tropic drugs behaviorally, but also the disposition of these agents and/ or their metabolites in regions of the central nervous system. There can hardly be a psychopharmacology without a neuropharmacology, and the latter would seem to depend upon a neurochemistry. There would appear to be variables that exert potent influences upon the disposition and action of psychotropic drugs, that also relate quite directly to their effects upon behavior; these include drug interactions, nutritional status, environmental effects such as temperature, photic and tactile stimulation, and stress, and the basal status upon which such drug treatment is superimposed. In this volume of Current Developments in Psychopharmacology, which will be the last to appear in this format, we have sought to focus upon a series of current topical reviews that highlight representative areas of experimental and clinical research activity in psychopharmacology. In the first chapter, Dr. Lagerspetz reviews a frequently neglected aspect of psychopharmacological research-the actions of psychoactive agents upon the nervous system and behavior of non-mammalian species.
Author: Marc Hertzman Publisher: John Wiley & Sons ISBN: 9780470749173 Category : Medical Languages : en Pages : 406
Book Description
Although clinical trials were virtually unheard of in psychiatry for many years, they are now the gold standard for judging whether drugs are safe and useful. But should they be? What is the true status of clinical trials? Even when they ostensibly demonstrate a benefit of a certain treatment, the strict patient selection criteria, poor compliance and high drop-out rate leave the conclusions open to question. Are the new treatments really better or more cost-effective than the old? Do they have fewer side effects? In this book the authors take a critical look at recent developments and present a series of trenchant and challenging observations. Section I examines the significant changes in law and the regulatory environment that have occurred during the past ten years. Has fossilization handicapped the US Food and Drug Administration in promoting treatment advances? How can the plethora of findings be regulated? This is particularly pertinent in genomic studies and there are two chapters addressing the impact of genomics on psychiatric research. This section also addresses the role of women in drug trials – a group long excluded but now demanding a part, for without testing how can optimal treatments be devised? The next two Sections highlight clinical trials in the major areas of psychiatric pharmacological treatment, including Mood Disorders, especially Bipolar, Anxiety Disorders, and addictions. Chapters on pharmacological treatments for Eating Disorders, Attention Deficit Disorder, Autism and Asperger’s Syndrome, and Impulse Control Disorder represent the latest thinking on these subjects. The final Section contains a consummate example of out-of-the [Western]- box thinking, namely consideration of herbal medicines – used by a large number of patients, with or without medical supervision. We conclude with a close look at the problem of side effects, then selected thoughts about methodology. Clearly written, the text provides immediate access to new developments across the spectrum of drug testing. Clinical Trials in Psychopharmacology: A Better Brain is provocative reading for psychiatrists, pharmacologists and all those interested in improved drug treatments for patients with mental illness. Raises questions about the conduct of trials and the credibility of their outcomes that are relevant not just in psychiatry but all areas of medicine Discusses the ethical problems in assessing outcomes in humans, including children
Author: David Rosenberg Publisher: John Wiley & Sons ISBN: 0470973765 Category : Medical Languages : en Pages : 475
Book Description
This book fulfils an urgent need for an updated text on pediatric psychopharmacology. It takes a unique approach in discussing recent findings within the context of current issues, including economic and political ones. The book covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, e.g, schizophrenia or bipolar disorder, but who are deemed to be at high risk. This is an active area of debate: such children are being treated in certain centers, while others reject this completely. The book addresses the antidepressant controversy, the placebo response and unique strategies for delineating this, and ways to optimize the differential between active medication and placebo. It reviews the impact of recent American Heart Association guidelines for monitoring children on stimulants and other psychotropics. It adheres closely to DSM-IV diagnostic criteria throughout. The book describes the use of newly approved drugs such as Lexapro for treating adolescent depression and the novel compound Intuniv. It covers the TADS and CAMS studies, which evaluated the use of SSRIs alone and in combination with cognitive behavioral therapy for adolescent depression. Other topics include treatment of bipolar disorders, the increasing popularity of generic equivalents, combination pharmacotherapy and the potential dangers of psychotropic medications. Third edition of the first ever book published on pediatric psychopharmacology from renowned editors. Incorporates current developments with regard to SSRIs, their indications and their safety issues, including possible associated suicidal behavior. Addresses concerns about cardiovascular side effects of the new stimulant medications available, and compares to other FDA-approved medications for ADHD. Features many tables, figures and pictorials, making it highly accessible and reader friendly.
Author: Jeffrey E. Kelsey Publisher: John Wiley & Sons ISBN: 0471794627 Category : Medical Languages : en Pages : 411
Book Description
Principles of Psychopharmacology for Mental Health Professionals addresses the current "split" model of mental health care, in which physicians provide pharmaco-therapy while non-prescribing practitioners oversee other services such as psychotherapy. Bringing these two areas together, this book familiarizes mental health professionals with the medications used to treat psychiatric disorders. Prepared by world-renowned psychopharmacologists and psychiatrists, this useful resource helps non-prescribing practitioners understand when and why a given medication is appropriate to use, when it is not indicated, and what potential side effects may occur. Also discussed are the appropriate times in therapy when a referral for a medication evaluation is indicated as well as how to broach this issue with the patient. Recognizing that there are almost always a number of medications from which to choose, the authors combine research outcomes with their extensive clinical experience to highlight the important considerations in selecting one medication over another. As an educational tool, the text encourages and supports clinicians who wish to increase patients' understanding of treatment. After an introduction and overview, chapters cover: * Basics of psychopharmacology * Attention-deficit hyperactivity disorder * Mood disorders * Sleep disorders * Schizophrenia * Cognitive disorders * Anxiety disorders * Personality disorders * Substance use disorders * Traumatic brain injury * Eating disorders * Side effects Every chapter includes diagnostic considerations, history of medication treatments, and emerging trends for each disease. Principles of Psychopharmacology for Mental Health Professionals lays out what psychotherapists and other mental health practitioners need to know about psychotropic medications, giving them and their patients an invaluable guide to the full array of treatments available.
Author: Joseph F. Goldberg Publisher: Cambridge University Press ISBN: 1108450741 Category : Medical Languages : en Pages : 611
Book Description
A practical guide translating clinical trials findings, across major psychiatric disorders, to devise tailored, evidence-based treatments.
Author: David Mintz, M.D. Publisher: American Psychiatric Pub ISBN: 1615371524 Category : Medical Languages : en Pages : 302
Book Description
"The troubling increase in treatment resistance in psychiatry has many culprits: the rise of biomedical psychiatry and corresponding sidelining of psychodynamic and psychosocial factors; the increased emphasis on treating the symptoms rather than the person; and a greater focus on the electronic medical record rather than the patient, all of which point to a breakdown in the person-centered prescriber-patient relationship. Psychodynamic Psychopharmacology illuminates a new path forward. It examines the psychological and interpersonal mechanisms of pharmacological treatment resistance, integrating research on evidence-based prescribing processes with psychodynamic insights and skills to enhance treatment outcomes for patients who are difficult to treat. The first part of the book explores the evidence base that guides how, rather than simply what, to prescribe. It describes precisely what psychodynamic psychopharmacology is and why its emphasis on combining the often-neglected psychosocial aspects of medication with biomedical considerations provides a more optimized approach to addressing treatment resistance. Part II delves into the psychodynamics that contribute to pharmacological treatment resistance, both when patients' ambivalence about their illness, the medication itself, or their prescriber manifests in nonadherence and when medications support a negative identity or are used as replacements for healthy capacities. Readers will gain basic skills for addressing the psychological and interpersonal dynamics that underpin both scenarios and will be better positioned to ameliorate interferences with the healthy use of medications. The final section of the book offers detailed technical recommendations for addressing pharmacological treatment resistance. It tackles issues that include countertransference-driven irrational prescribing; primitive dynamics, such as splitting and projective identification; and the overlap between psychopharmacological treatment resistance and the dynamics of treatment nonadherence and nonresponse in integrated and collaborative medical care settings. By putting the individual patient back at the center of the therapeutic equation, psychodynamic psychopharmacology, as outlined in this book, offers a model that moves beyond compliance and emphasizes instead the alliance between patient and prescriber. In doing so, it empowers patients to become more active contributors in their own recovery"--
Author: Joseph Wegmann Publisher: CMI Education Institute ISBN: 193612811X Category : Medical Languages : en Pages : 216
Book Description
Now in its second edition, Psychopharmacology: Straight Talk on Mental Health Medications is the definitive guide for healthcare professionals and anyone else seeking straightforward, concise and user-friendly information about mental disorders and the medications used to manage them. Fully revised and updated, this invaluable book has become the go-to favorite of clinicians, clients and family members intent on expanding their knowledge of Psychopharmacology Here's what you'll find: -Detailed descriptions of the disorders for which medications are most often prescribed -The very latest trends in psychiatric medication management and case study applications -Tips on medicating children, adolescents, older adults and expectant mothers -Herbals and alternative remedies: Do they work? Are they safe? -Answers to frequently asked questions -Resolving dilemmas - medication refusal, non-compliance, generic vs. brand drugs
Author: Daniel E. Casey
Author: W.B. Essman
Author: 
Author: Marc Hertzman
Author: David Rosenberg
Author: Walter Bernard Essman
Author: Jeffrey E. Kelsey
Author: Joseph F. Goldberg
Author: David Mintz, M.D.
Author: Joseph Wegmann